University of Pittsburgh

Vanderbilt University

Gene Therapy Systems, Inc.

Targeted Genetics Corporation

Pgr-solutions

Xiang Gao

Leaf Huang

Frank L Sorgi

Song Li

Philip L Felgner

Jing Ling

Yixian Huang

Xiaolan Zhang

Peter Wipf

Joel S Greenberger

Michael Wayne Epperly

Ralph Wilfred Paul

Aaron Garth Loomis

Nianke Wang

David L Sloane

A formulation includes a carrier agent formed by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, and a biologically active compound associated with the carrier agent.

Formulations and carrier systems including farnesylthiosalicylic moieties

A method of creating a formulation for a compound includes determining a compound interactive agent comprising at least one group that interacts with the compound, creating a carrier agent by conjugating at least one compound interactive domain comprising the at least one group that interacts with the compound with at least one hydrophilic domain, and combining the compound and the carrier agent to create the formulation. Creating the carrier agent may further include conjugating the at least one compound interactive domain with at least one hydrophobic domain so that the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain.

Formulations and carrier systems including compound interactive domains

A method of forming or creating a formulation for a compound to be delivered includes creating a carrier agent by conjugating at least one hydrophobic domain or hydrophobic compound with at least one hydrophilic domain or hydrophilic compound and associating the compound to be delivered with the carrier agent to create the formulation. The at least one hydrophobic compound has the formula: wherein R1 is a farnesyl group, a geranyl group or geranyl-geranyl group, X is O, S, SO, SO, NH or Se, Z is C&#x2014;Ror N, Ris H, CN, COR, SOR, CONRRor SONRR, wherein Rand Rare each independently H, an alkyl group, an alkenyl group, COM or SOM, wherein M is a cation and R, R, and Rare independently H, a carboxyl group, an alkyl group, an alkenyl group, an aminoalkyl group, a nitroalkyl group, a nitro group, a halo atom, an amino group, a mono-alkylamino group, a di-alkylamino group, mercapto group, a mercaptoalkyl group, an azido group or a thiocyanato group. A plurality of the carrier agents are adapted to assemble into a structure. The hydrophobic compound is cleavably conjugated to the at least one hydrophilic compound via a linkage which is labile in vivo.

Formulations and carrier systems including farnesylthiosalycylic moities

Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.

Stable lipid-comprising drug delivery complexes and methods for their production

There are provided multi-chain lipophilic polyamine compounds and derivatives thereof, pharmaceutical formulations comprising the same, method of making and using said compounds or formulations.

Multi-chain lipophilic polyamines

The present invention relates to synthetic cationic lipids, liposome formulations and the use of such compounds to introduce functional bioactive agents into cultured cells.

Cationic liposomes for gene transfer

The present invention relates to synthetic cationic lipids, liposome formulations and the use of the compounds to introduce functional bioactive agents into cultured cells.

In accordance with the present invention, there are provided amphiphilic polyamine compounds and derivatives thereof having the property of promoting transfection of polynucleotides and polypeptides into cells, and formulations comprising said compounds.

Amphiphilic polyamine compounds

Amphiphilic polyamide compounds and derivatives thereof having the property of promoting transfection of polynucleotides and polypeptides into cells, and formulations comprising said compounds.

Growing community of inventors

Nashville, TN, United States of America

Xiang Gao